pReOperative Dostarlimab and Novel Therapies in EndOmetrial Cancer

Summary

RODEO is a window of opportunity trial using dostarlimab in patients with newly diagnosed high-risk (stage 2-4) endometrial cancer who are suitable for primary surgery. Patients will receive 2 doses of dostarlimab (500mg IV day 1 and day 22) prior to surgery. The primary objective is to assess the pathological response rate to pre-operative dostarlimab and the secondary objectives are to assess the feasibility, toxicity, safety and efficacy of pre-operative dostarlimab.

Timeline

Start

2025-09-30

Primary completion

2030-04-30

Completion

2031-01-31

Drugs

Indications